2024
P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study
Lehto J, Aarnio R, Tuisku J, Sucksdorff M, Koivumäki E, Nylund M, Helin S, Rajander J, Danon J, Gilchrist J, Kassiou M, Oikonen V, Airas L. P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study. EJNMMI Research 2024, 14: 123. PMID: 39636350, PMCID: PMC11621262, DOI: 10.1186/s13550-024-01186-3.Peer-Reviewed Original ResearchPerilesional rimTracer bindingDisability progressionMS patientsMS brainsLesion rimWhite matterProgressive MS patientsPro-inflammatory microgliaRelapsed patientsSmoldering inflammationT1 lesionsMales compared to femalesNew-onsetProgressive patientsTracer uptakeParent tracerP2XDisease durationProgressive MSHealthy controlsPatientsPET studiesPerilesional areaFree fractionSex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals
Laaksonen S, Saraste M, Nylund M, Hinz R, Snellman A, Rinne J, Matilainen M, Airas L. Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals. Frontiers In Neurology 2024, 15: 1352116. PMID: 38445263, PMCID: PMC10913932, DOI: 10.3389/fneur.2024.1352116.Peer-Reviewed Original ResearchDistribution volume ratioNormal-appearing white matterMale MS patientsCortical gray matterMS patientsPositron emission tomographyTSPO bindingMultiple sclerosisDisease progressionHealthy individualsClinical disease progressionWhole-brainBrain positron emission tomographySex differencesMales compared to femalesFemale patientsHealthy womenDisability progressionGreater likelihoodGray matterHealthy controlsStudy cohortFemale controlsEmission tomographyBrain
2023
Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis
Wiendl H, Airas L, Chitnis T, Williams M, Nakahara J, Bermel R, Loop B, Hayek G, Bhatt A, Hunter B, Zhang Y, Karan R, Willi R, Kieseier B, Montalban X. Phase 3 REMODEL I/II Trials: Efficacy, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2023, 80: 105315. DOI: 10.1016/j.msard.2023.105315.Peer-Reviewed Original ResearchBruton's tyrosine kinaseDisease activitySerum neurofilament light chain concentrationNeurofilament light chain concentrationOpen-label extensionKey secondary endpointDisability Status ScaleNew oral treatmentRecent disease activityLight chain concentrationsPercentage of participantsCovalent BTK inhibitorImmune regulatory networkRelated neuroinflammationDisability progressionPrimary endpointSecondary endpointsT1 lesionsTyrosine kinaseOral treatmentRelapse rateT2 lesionsMulticenter studyMultiple sclerosisSafety profile
2020
Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data (1807)
Wolinsky J, Brochet B, Hartung H, Naismith R, Airas L, Coutant K, Koendgen H, Manfrini M, Overell J, Sauter A, Prajapati K, Kappos L. Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data (1807). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1807.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply